A Health Literate Patient-focused Approach to the Redesign of the Raltegravir (ISENTRESS) Pediatric Kit and Instructions for Use. Issue 1 (January 2022)

• Record Type: Journal Article
• Authors: Mills, Alexander; Myers, Laurie; Raudenbush, Casey; Vossen, David A.; Teppler, Hedy; Miteva, Yanna R.; Seeley, Suzanne; Homony, Brenda; Straus, Walter L.
• Is Part Of: Pediatric infectious disease journal. Volume 41:Issue 1(2022)
• Publication Date: 2022-01
• Subjects: raltegravir -- neonatal -- pediatric -- instructions for use -- health literacy -- patient-focused -- patients -- health literate -- product labeling -- patient labeling -- medication safety -- pediatric dosing -- HIV; Communicable diseases in children -- Periodicals; Infection in children -- Periodicals; 618.929
• DOI: 10.1097/INF.0000000000003334
• Languages: English
• ISSNs: 0891-3668

Abstract

Abstract : Background: Limited data exist regarding how medications for pediatric use can be developed to minimize medication errors. The integrase inhibitor raltegravir was developed for use in neonates (≥2 kg). Anticipating that neonatal administration would be performed primarily by mothers with varying degrees of health literacy, a health literate, patient-focused, iterative process was conducted to update/redesign the raltegravir granules for oral suspension pediatric kit and instructions for use (IFU) for neonatal use to be ready for regulatory submission. Methods: Prototypes of an updated/redesigned raltegravir IFU were systematically assessed through multi-stage, iterative testing and evaluation involving untrained lay individuals with varying levels of health literacy, healthcare professionals and health literacy experts. Results: This iterative process resulted in numerous refinements to the IFU and kit, including wording, layout, presentation, colored syringes and additional instructional steps. The revised raltegravir pediatric kit and IFU (to include neonatal dosing) were approved by the US Food and Drug Administration in 2017 and the European Union in 2018. No reported medication errors related to IFU utilization had been reported as of March 2021, reflecting >3 years of commercial use worldwide. Conclusions: This patient-focused process produced health literate instructions for preparing and administering an antiretroviral for neonatal use with complex dosing requirements. Testing demonstrated that lay users with a range of health literacy levels were able to accurately mix, measure and administer the product. This process demonstrates how a neonatal medication can be optimized for use through collaboration between the infectious disease expert community and a manufacturer.